The DOI matches its Crossref record.
Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors
Abstract
BACKGROUND: To review the case reports and case series of movement disorders ascribed to the use of serotonin selective reuptake inhibitors (SSRIs). METHOD: Reports of SSRI-induced extrapyramidal symptoms (EPS) in the literature were located using a MEDLINE search and review of bibliographies. RESULTS: Among the 71 cases of SSRI-induced EPS reported in the literature, the most common side effect was akathisia (45.1%), followed by dystonia (28.2%), parkinsonism (14.1%), and tardive dyskinesia-like states (11.3%). Among patients with Parkinson's disease treated with SSRIs, there were 16 cases of worsening parkinsonism. Patients who developed dystonia, parkinsonism, or tardive dyskinesia were older on average than patients with akathisia; 67.6% of affected patients were females. Fluoxetine, the most commonly prescribed SSRI to date, was implicated in 53 (74.6%) of cases of SSRI-induced EPS. Several reports (57.7%) were confounded by the concomitant use of other medications that can contribute to the development of EPS. CONCLUSION: SSRI-induced EPS are probably related to agonism of serotonergic input to dopaminergic pathways within the CNS. Several patient-dependent and pharmacokinetic variables may determine the likelihood that EPS will emerge. Although these side effects are infrequent, clinicians should be alert to the possibility of their occurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
The monoamine neurotransmitter disorders: an expanding range of neurological syndromes
Kurian, M. A., Gissen, P., Smith, M., Heales, S. J., & Clayton, P. T. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70141-7 · Cited by 351
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
Gerber, P. E., & Lynd, L. D. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17302 · Cited by 267
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Madhusoodanan, S., Alexeenko, L., Sanders, R., & Brenner, R. (2010) · Annals of Clinical Psychiatry · doi:10.1177/104012371002200303 · Cited by 121
Veazey, C., Cook, K. F., Stanley, M., Lai, E. C., & Kunik, M. E. (2009) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-009-9167-6 · Cited by 75
“Non-pharmaceutical treatment options are desirable in persons with chronic medical illnesses in general, and in the PD population, specifically (Oehlberg et al., 2008), given the possibility of adverse interactions between antidepressants and anti-parkinsonian medications (Leo, 1996).”
BackgroundA Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
Chouinard, G., Saxena, B., Bélanger, M.-C., Ravindran, A., Bakish, D., Beauclair, L., Morris, P., Vasavan Nair, N. P., Manchanda, R., Reesal, R., et al. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00188-8 · Cited by 57
24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder
Volkers, A. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00019-6 · Cited by 56
Avital, A., Gross-Isseroff, R., Stryjer, R., Hermesh, H., Weizman, A., & Shiloh, R. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.02.006 · Cited by 33
“…which is currently the gold standard in the treatment of NIA, is efficacious in only 40–70% of akathisic patients (Sachdev, 1995) and its use might be restricted in certain populations such as asthmatic, hypotensive, or depressed patients (Fleischhacker et al., 1990; Lipinski et al., 1984).”
BackgroundDysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.06.013 · Cited by 26
Acute dystonia resulting from abrupt bupropion discontinuation
Wang, H.-Y., Chou, W.-J., Huang, T.-Y., & Hung, C.-F. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.003 · Cited by 21
Deciphering Ibogaine’s Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses
Hwu, C., Havel, V., Westergaard, X., Mendieta, A. M., Serrano, I. C., Hwu, J., Walther, D., Lankri, D., Selinger, T. L., He, K., et al. (2025) · doi:10.1101/2025.03.04.641351 · Cited by 7
“79 Our results indicate that the SERT blockade and transient elevation of 5-HT induced by noribogaine in the NAc and striatum cannot explain its catalepsy mitigating effects.”
Metadata
- Authors
- Leo, R. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1996-10-15
- Volume
- 57
- Issue
- 10
- Pages
- 449-454
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1996673522
- Cited by
- 364
- References
- 0
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.